Crohn's disease trials in Germany

In Germany 40 Also abroad 422

40 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
Where
Berlin, Brandenburg An Der Havel, Duisburg, Hanover, Kiel, Leipzig, Ludwigshafen am Rhein, Lueneburg, Minden, Munich, Pforzheim, Remscheid, Rostock, Ulm
Age
18 years and over
People
567 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2024-518296-56-00 · EU 2024-518296-56-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Berlin, Brandenburg An Der Havel, Duisburg, Hanover, Kiel, Leipzig, Ludwigshafen am Rhein, Lueneburg, Minden, Munich, Pforzheim, Remscheid, Rostock, Ulm
Age
16 years to 80 years
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
Phase 1Not yet taking people in Germany
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Where
Berlin, Cottbus, Munich, Ulm
Age
18 years to 65 years
People
25
Run by
Sanofi
See details and how to joinNCT07923383 · EU 2026-525939-17-00
Phase 2Taking people
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Where
Berlin, Dachau, Duisburg, Frankfurt am Main, Halle (Saale), Heidelberg, Kiel, Leipzig, Magdeburg, Munich, Wipperfuerth, Wolfsburg
Age
18 years to 85 years
People
385 worldwide
Run by
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00
Phase 3Taking people
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Where
Frankfurt, Grevenbroich, Halle, Hanover, Leipzig, Potsdam
Age
18 years to 70 years
People
290 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00
Phase 2Taking people
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Where
Berlin, Dachau, Halle (Saale), Ludwigshafen am Rhein, Ulm
Age
18 years to 80 years
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483073 · EU 2025-524112-11-00
Phase 2Taking people
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Where
Berlin, Dachau, Halle, Ludwigshafen, Ulm
Age
18 years to 80 years
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483099
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Hamburg, Sankt Augustin
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
No phaseTaking people
A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
Where
Berlin
Age
18 years and over
People
500
Run by
Janssen-Cilag G.m.b.H
See details and how to joinNCT07102368
Phase 2/3Taking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Berlin, Dachau, Erlangen, Halle (Saale), Hanover, Jerichow, Kiel, Leipzig, Lueneburg, Oldenburg in Holstein, Rostock, Ulm
Age
18 years and over
People
1,092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
Phase 3Taking people
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Where
Berlin, Erlangen, Grevenbroich, Jena, Kiel, Ludwigshafen am Rhein, Mannheim, München
Age
18 years and over
People
530 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07499232
Phase 3Taking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Augsburg, Berlin, Dachau, Dresden, Erlangen, Frankfurt Am Main, Halle (Saale), Halle Saale, Hanover, Kassel, Kiel, Leipzig, Mannheim, Munich, Regensburg, Rostock, Ulm
Age
18 years and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
Phase 2Taking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Frankfurt am Main, Frankfurt Am Main, Kiel, Ludwigshafen am Rhein, Mannheim, Tuebingen, Ulm
Age
18 years to 75 years
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
Phase 2Taking people
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Where
Jena, Kiel, Minden, Potsdam, Ulm
Age
18 years to 75 years
People
99 worldwide
Run by
Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00
Phase 4Taking people
A study to measure mirikizumab levels in breast milk of lactating participants receiving mirikizumab therapeutically for an approved indication
Where
Frankfurt
People
16 worldwide
Run by
Eli Lilly & Co.
See details and how to join2025-522362-78-00 · EU 2025-522362-78-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Berlin, Heidelberg, Jena, Potsdam, Ulm
Age
16 years to 80 years
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Berlin, Dachau, Dresden, Duisburg, Halle, Hamburg, Herne, Jerichow, Kiel, Leipzig, Ludwigshafen am Rhein, Lüneburg, Minden, Remscheid, Tübingen, Ulm, Würzburg
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
Phase 3Taking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Kiel, Leipzig, Ulm
Age
16 years to 80 years
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07184944
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Muenster, Munich
Age
2 years to 17 years
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Berlin, Frankfurt am Main, Frankfurt Am Main, Halle Saale, Hanover, Jena, Ulm
Age
16 years to 80 years
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
Phase 2Taking people
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
Where
Berlin, Frankfurt am Main, Munich, Tuebingen, Ulm
Age
18 years and over
People
160 worldwide
Run by
Agomab Spain S.L.U.
See details and how to join2026-525197-19-00 · EU 2026-525197-19-00
No phaseTaking people
Impact of Diet and Lifestyle Modification on the Intestinal Barrier Integrity in Crohn's Disease
Where
Bamberg
Age
18 years and over
People
30
Run by
Universität Duisburg-Essen
See details and how to joinNCT06719778
Phase 3Taking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
Mainz, Munich
Age
2 years to 19 years
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606
No phaseTaking people
Wild Blueberries in Colitis
Where
Bamberg
Age
18 years and over
People
60
Run by
Universität Duisburg-Essen
See details and how to joinNCT06698601
Phase 2Taking people
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Where
Berlin, Dresden, Erlangen, Essen, Frankfurt am Main, Frankfurt Am Main, Freiburg im Breisgau, Fulda, Halle (Saale), Homburg, Kiel, Leipzig, Ludwigshafen am Rhein, Lueneburg, Mannheim, Munich, Regensburg, Ulm
Age
18 years to 75 years
People
590 worldwide
Run by
AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00